title: Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays.
abstract: Although hypomethylation was the originally identified epigenetic change in cancer, it was overlooked for many years in preference to hypermethylation. Recently, gene activation by cancer-linked hypomethylation has been rediscovered. However, in gastric cancer, genome-wide screening of the activated genes has not been found. By using microarrays, we identified 1,383 gene candidates reactivated in at least one cell line of eight gastric cancer cell lines after treatment with 5-aza-2'deoxycytidine and trichostatin A. Of the 1,383 genes, 159 genes, including oncogenes ELK1, FRAT2, R-RAS, RHOB, and RHO6, were further selected as gene candidates that are silenced by DNA methylation in normal stomach mucosa but are activated by DNA demethylation in a subset of gastric cancers. Next, we showed that demethylation of specific CpG sites within the first intron of R-RAS causes activation in more than half of gastric cancers. Introduction of siRNA into R-RAS-expressing cells resulted in the disappearance of the adhered cells, suggesting that functional blocking of the R-RAS-signaling pathway has great potential for gastric cancer therapy. Our extensive gene list provides other candidates for this class of oncogene.
authors.affiliation: Genetics Division, Center of Medical Genomics, and Central Animal Laboratory, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo, Japan.
authors.forename: Michiko
authors.initials: M
authors.lastname: Nishigaki
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Aoyagi
authors.forename: Inaho
authors.initials: I
authors.lastname: Danjoh
authors.forename: Masahide
authors.initials: M
authors.lastname: Fukaya
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Yanagihara
authors.forename: Hiromi
authors.initials: H
authors.lastname: Sakamoto
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Yoshida
authors.forename: Hiroki
authors.initials: H
authors.lastname: Sasaki
mesh_terms: D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D001483:Base Sequence; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000235:genetics; D016000:Cluster Analysis; D018899:CpG Islands; D019175:DNA Methylation / Q000187:drug effects; D000077209:Decitabine; D020558:GTP Phosphohydrolases / Q000096:biosynthesis / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics*; D015894:Genome, Human; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D007438:Introns; D008969:Molecular Sequence Data; D020411:Oligonucleotide Array Sequence Analysis; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics; D013274:Stomach Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D015533:Transcriptional Activation / Q000235:genetics; D018631:ras Proteins / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D006877:Hydroxamic Acids; D034741:RNA, Small Interfering; C012589:trichostatin A; D000077209:Decitabine; D020558:GTP Phosphohydrolases; C085929:RRAS protein, human; D018631:ras Proteins; D001374:Azacitidine